Management of anaemia in patient with cancer: Results of the F-ACT study (French Anaemia Cancer Treatment);Prise en charge de l'anémie chez les patients présentant une pathologie maligne: Résultats de l'étude F-ACT (French Anaemia Cancer Treatment)

Bulletin du Cancer

Volumn 94, Issue 10, 2007, Pages 907-914

  Guardiola, Emmanuel ^a   Morschhauser, Franck ^b   Zambrowski, Jean Jacques ^c   Antoine, Eric Charles ^d  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c BICHAT HOSPITAL   (France)

^d Clinique Hartmann   (France)

Author keywords

Anaemia; Erythropoiesis; Malignant haematological diseases; Prevalence; Solid tumours; Transfusion

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER; CANCER LOCALIZATION; CONSULTATION; CONTROLLED STUDY; ERYTHROPOIESIS; FEMALE; HEALTH SURVEY; HEMATOLOGIC MALIGNANCY; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; RETROSPECTIVE STUDY; SOLID TUMOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; BLOOD TRANSFUSION; ERYTHROPOIESIS; FEMALE; FRANCE; HEALTH CARE SURVEYS; HEMATINICS; HEMATOLOGIC NEOPLASMS; HEMOGLOBIN A; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PREVALENCE; RETROSPECTIVE STUDIES;

EID: 36248976610     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2007.0482     Document Type: Article

References (11)

1. Guardiola E. Traitement de l'anémie en cancérologie : transfusion ou érythropoïétine? Oncologie 2000 ; 2 : 113-9.
2. Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer : a systemic, quantitative review. Cancer 2001 ; 91 : 2214-21.
3. Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease-response or tumor type : results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998 ; 16 : 3112-25.
4. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy : results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001 ; 19 : 2865-74.
5. Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, et al. Use of epoetin in patients with cancer : evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002 ; 20 : 1083-107.
6. Henry DH. Guidelines for the use of epoetin in cancer patients : a much-needed step forward in standardizing anemia treatment. Blood 2003 ; 102 : 2697-8.
7. Ludwig H, Van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascon P, et al. The European Cancer Anaemia Survey (ECAS) : a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004 ; 40 : 2293-306.
8. Schneider M. Fréquence de l'anémie chez les patients français atteints de tumeurs solides ou d'hémopathies malignes : résultats de l'European Cancer Anaemia Survey (ECAS). Oncologie 2005 ; 7 : 397-402.
9. Hill C, Doyon F. Frequency of cancer in France. Bull Cancer 2003 ; 90 : 207-13.
10. Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 2004 ; 10 : 2201-16.
11. Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, et al. Recombinant human erythropoietins and cancer patients : updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006 ; 98 : 708-14.